Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
GlaxoSmithKline
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Stephen_Dilly
|
| gptkbp:focusesOn |
oncology
hematology |
| gptkbp:formerName |
gptkb:YM_BioSciences
|
| gptkbp:foundedYear |
2003
|
| gptkbp:headquartersLocation |
gptkb:San_Mateo,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sierra Oncology
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:momelotinib
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:SRRA
|
| gptkbp:website |
https://www.sierraoncology.com/
|
| gptkbp:bfsParent |
gptkb:Frazier_Healthcare_Ventures
gptkb:LianBio |
| gptkbp:bfsLayer |
7
|